Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human angiotensin receptor subtypes

R D Smith1, P B Timmermans

  • 1DuPont Merck Pharmaceutical Company, Wilmington, Delaware.

Current Opinion in Nephrology and Hypertension
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacological properties of angiotensin II receptor antagonists.

The Canadian journal of cardiology·1999
Same author

Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics.

Hypertension research : official journal of the Japanese Society of Hypertension·1999
Same author

Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors.

Proceedings of the National Academy of Sciences of the United States of America·1999
Same author

Rationale, background, and design of the randomized angiotensin receptor antagonist--angiotensin-converting enzyme inhibitor study (RAAS).

The American journal of cardiology·1996
Same author

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.

Journal of medicinal chemistry·1996
Same author

The diversified pharmacology of angiotensin II-receptor blockade.

Blood pressure. Supplement·1996
Same journal

Sex differences in renal acid-base regulation.

Current opinion in nephrology and hypertension·2026
Same journal

Primary prevention of chronic kidney disease in type 2 diabetes mellitus with sodium-glucose cotransporter 2 inhibitors.

Current opinion in nephrology and hypertension·2026
Same journal

Financial and policy challenges of delivering kidney replacement therapies in resource-limited settings.

Current opinion in nephrology and hypertension·2026
Same journal

The role of kir4.1/Kir5.1 in mediating the effect of angiotensin-II on Na-Cl-cotransporter.

Current opinion in nephrology and hypertension·2026
Same journal

Role of the calcium-sensing receptor in regulating calcium transport in the thick ascending limb.

Current opinion in nephrology and hypertension·2026
Same journal

Social determinants of chronic kidney disease: from association to clinical and population action.

Current opinion in nephrology and hypertension·2026
See all related articles

New research explores angiotensin receptors, focusing on AT1 and AT2 subtypes. AT1-selective antagonists like losartan effectively block angiotensin II effects, showing promise for inhibiting the human angiotensin system.

Area of Science:

  • Pharmacology
  • Cardiovascular Research
  • Molecular Biology

Background:

  • Knowledge of angiotensin receptors has expanded due to subtype-specific antagonists and AT1 receptor cloning.
  • The significance of AT2 receptors remains unclear, while AT1 antagonists block known angiotensin II effects.

Purpose of the Study:

  • To review the current understanding of angiotensin receptor subtypes and their antagonists.
  • To highlight the role of AT1-selective agents in inhibiting the angiotensin system.

Main Methods:

  • Review of scientific literature on angiotensin receptor research.
  • Analysis of the effects of AT1-selective antagonists, such as losartan.

Main Results:

  • Nonpeptide, AT1-selective antagonists effectively block angiotensin II actions in mammalian cells.

Related Experiment Videos

  • AT1 receptor subtypes (AT1A, AT1B) have been identified in rodents, but not functionally distinguished in humans.
  • The AT2 receptor has been cloned, and research is ongoing for its role in fetal tissue, brain, and cardiovascular cells.

    • Conclusions:

    • AT1-selective agents are increasingly recognized as effective inhibitors of the human angiotensin system.
    • Further research is needed to clarify the clinical relevance of angiotensin II receptor subtypes.